REPARA Study: REgistry of PAtients With bioResorbable Device in Daily Clinical prActice (REPARA)

Registry of Patients With Bioresorbable Device in Daily Clinical Practice. REPARA Study

A multicentre, observational, prospective device registry, with no control group, designed to evaluate the efficacy and safety of the bioresorbable coronary device, used according to the indications of use, in daily clinical practice in a consecutive number of patients undergoing PCI in de novo coronary artery lesions. A total of 1,500 patients are planned to be included in the registry.

Study Overview

• Status: Unknown
• Conditions: Coronary Artery Lesions With Implantation of Coronary Device

Detailed Description

The patients will be included consecutively at each site for one year. They will be individuals from both sexes, requiring endovascular intervention and meeting the authorised criteria for the indications of use of the device to be used and where dual anti-platelet therapy (DAPT) with aspirin and thienopyridines is considered.

STUDY OBJECTIVES To evaluate the MACE rate after implantation of the bioresorbable coronary device in patients with de novo coronary artery lesions, where a follow-up of 12 months will be performed.

Primary objective:

MACE rate at 12 months of follow-up:

Cardiac death Myocardial infarction TLR driven by ischaemia of the lesion treated or of the region of 5 mm proximally or distally to the site of implantation of the device (ID-TLR).

Secondary objectives:

• Angina
• Death due to any cause.
• Myocardial infarction of any type (MI: QMI, NQMI, TV, NTV)
• All TLR driven or not by ischaemia
• All TVR driven or not by ischaemia.
• All coronary revascularisations performed (PCI vs CABG)
• Device thrombosis (acute, sub-acute, late) and evidence (definitive, probable, possible).
• Immediate success of the device.
• Immediate success of the procedure.
• Rate of patients with DAPT at < 1 month, 1-3 months, 3-6 months, and 6-12 months and relationship with the occurrence of events
• Composite endpoints:

Cardiac death, TV-MI and ID-TLR: (Target Lesion Failure (TLF)) Cardiac death, any myocardial infarction (MI) and ID-TVR: (Target Vessel Failure (TVF))

• Rate of overlapping devices: characteristics and relationship with occurrence of events
• Collection of imaging data of the cases where, according to the judgement of the investigator, intravascular imaging tests have been performed (IVUS, OCT).

• Study Type: Observational
• Enrollment (Actual): 2440

Contacts and Locations

Study Locations

• Spain
  • Madrid, Spain, 28041
    • Hospital 12 de Octubre

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patients with native coronary artery de novo lesions with indication for revascularization with a coronary device

Description

Inclusion Criteria:

• Patient must be at least 18 years of age at the time of signing the Informed Consent Form
• Patient is to be treated for de novo coronary lesions in a native coronary artery and amenable to receive a bioresorbable device
• The length of the treated lesion should be inferior to the nominal length of the device (12 mm, 18 mm, 28 mm) with a reference vessel diameter > 2 mm y < 3,8 mm.
• The patient will not have any relative contraindication for double antiplatelet therapy, with aspirin indefinitely and with a thienopyridine for at least 6 months

Exclusion Criteria:

• Cardiogenic shock
• Left main disease
• Aortocoronary graft
• Intrastent restenosis
• Potentially child-bearing women with no contraceptive methods
• Pregnant or breast-feeding women

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
BVS patients; Use of bioresorbable coronary device, according to the indications of use, in daily clinical practice, in patients undergoing PCI in de novo coronary artery lesions.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
MACE rate (major adverse cardiac events) at 12 months of follow-up: Cardiac death; Myocardial infarction; Target lesion revascularisation (TLR) ischemia-driven: Cardiac Death/All MI/ID-TLR	Clinical follow-up at 12 months

Secondary Outcome Measures

Outcome Measure	Time Frame
Immediate success of the device/procedure	1 day
Cardiac death	12 months
Myocardial infarction	12 months
Scaffold/Stent Thrombosis: Timing and Evidence	12 months
Target lesion/vessel revascularization (TLR/TVR)	12 months
Angina Events	12 months
Rate of patients with DAPT at 12 months	12 months
Rate of overlapping devices and characteristics	12 months

Collaborators and Investigators

• Sponsor: Sección Hemodinamica y Cardiologia Intervencionista
• Investigators: Principal Investigator: Felipe Hernandez, MD, Seccion Hemodinamica y Cardiologia Intervencionista

Study record dates

Study Major Dates

• Study Start: January 1, 2014
• Primary Completion (Actual): September 1, 2015
• Study Completion (Anticipated): October 1, 2016

Study Registration Dates

• First Submitted: September 23, 2014
• First Submitted That Met QC Criteria: September 30, 2014
• First Posted (Estimate): October 3, 2014

Study Record Updates

• Last Update Posted (Estimate): July 18, 2016
• Last Update Submitted That Met QC Criteria: July 15, 2016
• Last Verified: July 1, 2016

More Information

Terms related to this study

• Keywords: Coronary artery disease; angioplasty; bioresorbable device
• Other Study ID Numbers: COR-BVS-2013-01